Vemurafenib: the first drug approved for BRAF-mutant cancer

@article{Bollag2012VemurafenibTF,
  title={Vemurafenib: the first drug approved for BRAF-mutant cancer},
  author={Gideon Bollag and James H. Tsai and Jiazhong Zhang and Chao Michael Zhang and Prabha N. Ibrahim and Keith B. Nolop and Peter Hirth},
  journal={Nature Reviews Drug Discovery},
  year={2012},
  volume={11},
  pages={873-886}
}
The identification of driver oncogenes has provided important targets for drugs that can change the landscape of cancer therapies. One such example is the BRAF oncogene, which is found in about half of all melanomas as well as several other cancers. As a druggable kinase, oncogenic BRAF has become a crucial target of small-molecule drug discovery efforts. Following a rapid clinical development path, vemurafenib (Zelboraf; Plexxikon/Roche) was approved for the treatment of BRAF-mutated… Expand
Chapter Twenty-Six – Case History: Vemurafenib, a Potent, Selective, and First-in-Class Inhibitor of Mutant BRAF for the Treatment of Metastatic Melanoma
TLDR
Vemurafenib was discovered as part of a series of orally available, mutant-selective, BRAF inhibitors using “scaffold-based drug discovery” platform, which employs early co-crystallography to enhance the screening and chemistry optimization paradigm. Expand
Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma
TLDR
The effects of the new therapeutic agents against melanoma and the underlying biology of these BRAF inhibitors are summarized. Expand
BRAF inhibitors: the current and the future.
TLDR
There are questions remaining to be answered to enable more efficient use of BRAFi in cancer therapy, and intrinsic and acquired resistance remain the key challenges in BRAFi therapy. Expand
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
TLDR
This Review describes the development of BRAF inhibitors and the results that have emerged from their analysis in both the laboratory and the clinic and enumerates mechanisms of resistance to BRAF inhibition that have been characterized. Expand
Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment
TLDR
It is found that even the most synergistic drug pairs are effective only in a discrete number of cell lines, underlying a strong context dependency for synergy, with strong, widespread synergies often corresponding to non-specific or off-target drug effects such as multidrug resistance protein 1 (MDR1) transporter inhibition. Expand
BRAF and MEK Gene Rearrangements in Melanoma: Implications for Targeted Therapy
TLDR
An effective strategy to build upon the successes seen with dabrafenib and trametinib monotherapies has been to combine these agents (CombiDT), with the goal of further improving response rates and delaying resistance. Expand
Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research.
TLDR
The need for future multi-institutional studies to confirm the clinical validity of different therapeutic strategies on a large scale population is commended and the role of molecular genetics and various targeted therapies that have been developed to treat advanced stages of melanoma is provided. Expand
Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells.
TLDR
Several genes and miRNAs were differentially regulated in the drug-resistant and -sensitive cell lines and might be considered as prognostic and/or diagnostic resistance biomarkers in melanoma drug resistance. Expand
Targeting Oncogenic BRAF: Past, Present, and Future
TLDR
This review highlights common mechanistic themes that underpin different classes of resistance mechanisms against BRAF-targeted therapies and discusses tumor heterogeneity and co-occurring molecular alterations as a potential source of therapy resistance. Expand
Targeting B-RAF: The Discovery and Development of B-RAF Inhibitors
TLDR
This chapter describes the role of B-RAF signaling in the MAPK pathway, the regulation and structure of the BRAF kinase, and how the mutation leads to constitutive activation and the mechanisms by which resistance develops. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 151 REFERENCES
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
TLDR
The discovery and continuing development of sorafenib is described, the first oral multikinase inhibitor that targets Raf and affects tumour signalling and the tumour vasculature. Expand
Cancer research. Melanoma drug vindicates targeted approach.
TLDR
The only metastatic melanoma drug, dacarbazine, was approved by the U.S. Food and Drug Administration in 1975 and has a 15% response rate, so when a phase I trial for a new targeted molecular therapy that binds to and inactivates the BRAF protein reported a 70% response rates, it shocked the field. Expand
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
TLDR
The discovery and continuing development of sorafenib is described, the first oral multikinase inhibitor that targets Raf and affects tumour signalling and the tumour vasculature. Expand
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
TLDR
To anticipate potential mechanisms of acquired resistance to RAF inhibitors during the course of treatment, drug-resistant clones are established from a human melanoma-derived cell line harboring the recurrent V600E activating BRAF mutation, which exhibits exquisite sensitivity to AZ628, a selective RAF kinase inhibitor. Expand
Oncogenic BRAF is required for tumor growth and maintenance in melanoma models.
TLDR
Inducible short-hairpin RNA xenograft models are developed to examine the in vivo efficacy of inhibiting oncogenic BRAF and show that tumor regression resulting from BRAF suppression is inducible, reversible, and tightly regulated in these models. Expand
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
TLDR
The findings suggest that the administration of vemurafenib in combination with standard-of-care or novel targeted therapies may lead to enhanced and sustained clinical antitumor efficacy in CRCs harboring the BRAF(V600E) mutation. Expand
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
TLDR
An RNA-interference-based genetic screen in human cells is performed to search for kinases whose knockdown synergizes with BRAF(V600E) inhibition, and it is reported that blockade of the epidermal growth factor receptor (EGFR) shows strong synergy with BRAFs inhibition. Expand
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
TLDR
The structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity, and a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily are described, demonstrating that BRAF-mutant melanomas are highly dependent on B- RAF kinases activity. Expand
RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors
TLDR
Orthotopic implants of patient tumors in mice may predict prognosis and treatment response for melanoma patients and a subpopulation of human melanoma tumors responds to RAF265 and can be characterized by gene mutation and gene expression profiles. Expand
Inhibition of mutated, activated BRAF in metastatic melanoma.
TLDR
Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients. Expand
...
1
2
3
4
5
...